Made by Hemp 1000MG Hemp Extract
Chemical contamination: product contains elevated levels of undeclared lead.
Every FDA drug recall initiated in 2020, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.
930 recalls, newest first.
Chemical contamination: product contains elevated levels of undeclared lead.
Chemical contamination: product contains elevated levels of undeclared lead.
Chemical contamination: product contains elevated levels of undeclared lead.
Chemical contamination: product contains elevated levels of undeclared lead.
Chemical contamination: product contains elevated levels of undeclared lead.
Chemical contamination: product contains elevated levels of undeclared lead.
Chemical Contamination: product contains elevated levels of undeclared lead.
TEMPERATURE ABUSE: Complaint received from customer that product was received in a non-refrigerated state.
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.
Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.
Subpotent Drug: Out-of-Specification potency results at the 30-day stability timepoint.
Superpotent Drug: The beginning portion of the batch appears to be approximately 25% superpotent for active ingredient Meradimate.
Presence of foreign tablet: Consumer complaint of Clozapine Tablets 50mg being present in 500 count bottles of Clozapine Tablets USP 100mg.
CGMP Deviation: Potential presence of Nitrosodimethylamine (NDMA) Impurity above the established levels.
Subpotent Drug: active ingredient ethanol tested below label claim and there is presence of undeclared isopropyl alcohol.
Subpotent Drug: active ingredient ethanol tested below label claim and there is presence of undeclared isopropyl alcohol.
Subpotent Drug: active ingredient ethanol tested below label claim and there is presence of undeclared isopropyl alcohol.
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.
Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.
Labeling Not Elsewhere Classified: The statement Pharmacist: Dispense with the accompanying Medication Guide was not included on the carton label.
Labeling: Label mix up: Bottles labeled as aripiprazole 2 mg, 30 count had aripiprazole 5 mg tablets, 100 count.
Subpotent Drug: Out of specification for assay at the 9-month interval for Nystatin Cream, USP.
Subpotent Drug: Out of specification for assay at the 9-month interval for Nystatin Cream, USP.